• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region

Educational Resources

Categories
Dermatology: 
  • Atopic dermatitis
  • Chronic spontaneous urticaria
  • Prurigo nodularis
Gastroenterology: 
  • Eosinophilic esophagitis
Pulmonology: 
  • Asthma
  • Chronic obstructive pulmonary disease
  • IL-33
Rhinology: 
  • Chronic rhinosinusitis with nasal polyps
Filters
Topic: 
  • Burden of disease
  • Pathophysiology
  • Guidelines and recommendations
  • Clinical management
  • Co-existing type 2 inflammatory diseases
Format: 
  • Expert Video
  • Podcast
  • Slide presentation
  • Infographic
  • Video animation
  • Interactivity
Length: 
  • Short (<5 minutes)
  • Medium (5-15 minutes)
  • Long (> 15 minutes)
Sort by: Newest
  • Newest
  • Oldest
  • A-Z
  • Z-A
Mechanisms of Production and Clinical Impact of IgE
Pulmonology
5 min
videoanimation

Mechanisms of Production and Clinical Impact of IgE

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
4 min
videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Exploring the Mechanisms of FeNO Production in the Lungs
Pulmonology
4 min
videoanimation

Exploring the Mechanisms of FeNO Production in the Lungs

How Type 2 Inflammation Drives Eosinophils in Asthma
Pulmonology
4 min
videoanimation

How Type 2 Inflammation Drives Eosinophils in Asthma

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
Dermatology
3 min
expert video

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

On the Surface: Restoring the Skin Barrier in Patients with AD
Dermatology
2 min
expert video

On the Surface: Restoring the Skin Barrier in Patients with AD

ADVENT On Air | Be on the Lookout for EoE: The Importance of Early Diagnosis
Gastroenterology
18 min
Podcast

ADVENT On Air | Be on the Lookout for EoE: The Importance of Early Diagnosis

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
5 min
expert video

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
4 min
expert video

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
Dermatology
4 min
expert video

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

    1234
    ...
    17